Back to journals
Academic Journal

Journal of the Neurological Sciences

3 Papers Indexed in Blossom

Data updated

Research Footprint

Journal of the Neurological Sciences has 3 tracked papers indexed in Blossom (2020–2024) from 13 authors, most often covering Psilocybin, MDMA and Nitrous Oxide, across Depressive Disorders, Anxiety Disorders and Treatment-Resistant Depression (TRD).

Published Papers

Paywallindividual

Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial

This double-blind, placebo-controlled study (n=10) assesses the safety and efficacy of repeated pulse administration of psilocybin (10mg/70kg, 3x in 15 days) in cluster headache patients. Following the initial trial, eligible participants received a psilocybin pulse at least 6 months later and kept headache diaries for 8 weeks. Results indicate a significant reduction in cluster attack frequency following the psilocybin pulse, suggesting potential therapeutic benefits.

Published
Journal
Journal of the Neurological Sciences
Authors
Schindler, E. A. D., Sewell, R. A., Gottschalk, C. H., Flynn, L. T., Zhu, Y., Pittman, B. P., Cozzi, N. V., D’Souza, D. C.
Open Accessmeta

Nitrous Oxide: an emerging novel treatment for treatment-resistant depression

This review (2021) explores the possibilities of using Nitrous Oxide (NO2) for treating treatment-resistant depression (TRD). The use of NO2 as a psychiatric intervention is discussed along with its possible mechanism of action. Its antidepressant effects are believed to be mediated through the NMDA receptor.

Published
Journal
Journal of the Neurological Sciences
Authors
Quach, D. F., de Leon, V. C., Conway, C. R.
Open Accessmeta

A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses

This review (2020) presents modern human studies into psychedelic drugs, including psilocybin, LSD, MDMA, and ayahuasca in treating various psychiatric illnesses, including treatment-resistant depression, post-traumatic stress disorder, end-of-life anxiety, and substance use disorders. Safety and efficacy data are also presented from both human and animal studies.

Published
Journal
Journal of the Neurological Sciences
Authors
Chi, T., Gold, J. A.

Quick Facts

Papers Indexed
3
h-Index
158
Open Access
No
Publisher
Elsevier
Country
Netherlands
Website
Visit